Common virus may improve skin cancer treatment outcomes
1 May 2025
May is Skin Cancer Awareness Month, and a new study with input from researchers in NDM’s units has revealed that a common virus may positively influence how skin cancer patients respond to current treatments.
New study confirms malaria drug safe for children and reduces disease burden
30 April 2025
A major study in The Lancet Infectious Diseases confirms that single low-dose primaquine is safe and effective in reducing malaria transmission in young children. Analysing data from over 6,000 patients, researchers found it effective even in young children and areas with high malaria burden.
Study finds that Treg depletion suppresses tumour growth
24 April 2025
A new study, co-lead by Dr Felipe Galvez-Cancino from the Centre for Immuno-Oncology, has shown that Treg cell depletion can suppress tumour growth in one of the deadliest types of cancer.
New combination therapy developed for acute myeloid leukaemia
17 April 2025
Researchers in the Shi group at Ludwig Cancer Research Oxford have developed a new combination therapy for acute myeloid leukaemia, showing therapeutic promise by promoting differentiation of immature blood cells.
Study identifies direct link between inflammation and asthma attacks
10 April 2025
An international consortium of respiratory scientists, including researchers from NDM’s Experimental Medicine Division, have shed light on the role of inflammation in asthma. Through their findings, they have provided a new way of predicting and preventing asthma attacks.
Up to £16.5 million awarded to global consortium to overcome obstacles in infectious disease research
9 April 2025
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has been awarded up to £16.5 million to build on its globally-recognised efforts to prevent illness and deaths from epidemic-prone infectious diseases.
Research team receive £5.5m in funding to transform bowel cancer care
1 April 2025
Cancer Research UK and partners have committed £5.5 million in funding to form a world-leading research team, co-led by NDM’s Professor Simon Leedham. The team’s goal is to make personalised medicine a reality for people with bowel cancer.
First human trial of aerosol vaccine delivery launched
27 March 2025
The Jenner Institute, in partnership with the Coler Lab at Seattle Children’s Research Institute (SCRI), is set to begin a new clinical trial to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-man aerosol mycobacterial challenge infection model with healthy adult volunteers.
Oxford marks World Tuberculosis Day as vaccine trials continue
24 March 2025
Thanks to cutting edge research at NDM's Jenner Institute and Oxford University Clinical Research Unit (OUCRU), Oxford remains at the forefront of research to develop new vaccines to protect against this devastating disease.
Lower-dose yellow fever vaccine as effective as the current standard
20 March 2025
In a recent study, researchers at the KEMRI Wellcome Trust Research Programme in Kenya have discovered that a low-dose of the yellow fever vaccine is as effective as the current standard dose.
Prioritising research to better address high-consequence outbreaks
19 March 2025
A new paper published in BMC Medicine analyses research prioritisation approaches for high-consequence pathogens.
‘Brain bins’ in neck lymph nodes offer clues about brain health
13 March 2025
Scientists have found another clue about how brain health is maintained and how this might be affected by ageing and Alzheimer’s disease, according to a new paper.
New paper outlines ethical issues in clinical metagenomics
12 March 2025
Researchers have published the first paper mapping clinical ethics questions raised by new metagenomic techniques for diagnosing disease in clinical practice.
Immune response may be harnessed to control HIV
11 March 2025
Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.
Melanoma progression driven in part by fatty acid uptake
4 March 2025
The Goding lab, working in collaboration with the University Rey Juan Carlos, have shown that fatty acid uptake activates an AXL-CAV1-β-catenin axis to drive melanoma invasiveness.
Study finds previously unidentified genetic determinants of rare disease
28 February 2025
A landmark study involving researchers from NDM’s Centre for Human Genetics has identified 69 previously unidentified genetic determinants of rare disease, including uncommon forms of epilepsy and schizophrenia.
Researchers receive funding to develop new therapies for drug-resistant tuberculosis
25 February 2025
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded £5 million to a group of interdisciplinary researchers from NDM and other departments at the University, to develop new therapies for drug-resistant tuberculosis.
Bangladesh malaria vaccine and drug administration trial begins
24 February 2025
After more than a year of community engagement and preparation in 100 villages with over 12,000 inhabitants across the Chittagong Hill Tracts, a mass malaria vaccine (R21/Matrix M) and drug administration (DHA, piperaquine, and single low dose primaquine) study was launched on 15 February.
Advances in AI can help prepare the world for the next pandemic
21 February 2025
In the first study of this kind, NDM’s Pandemic Sciences Institute and Oxford researchers partner with global colleagues to outline how artificial intelligence can transform infectious disease research and save more lives.
Researchers develop AI-powered tools to improve pneumonia care
19 February 2025
A team of researchers at OUCRU was recently awarded a multi-million-dollar Discovery Award from the Wellcome Trust to develop AI tools to advance pneumonia research.